NEW YORK, Nov. 25, 2020 /PRNewswire/ --Amid the COVID-19 crisis, the global market for Cell Harvesting estimated at US$233.2 Million in the year 2020, is projected to reach a revised size of US$381.4 Million by 2027, growing at a CAGR of 7.3% over the period 2020-2027.Manual, one of the segments analyzed in the report, is projected to grow at a 7.9% CAGR to reach US$284.4 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Automated segment is readjusted to a revised 5.6% CAGR for the next 7-year period. This segment currently accounts for a 28.3% share of the global Cell Harvesting market.
Read the full report: https://www.reportlinker.com/p05798117/?utm_source=PRN
The U.S. Accounts for Over 30.9% of Global Market Size in 2020, While China is Forecast to Grow at a 10.4% CAGR for the Period of 2020-2027
The Cell Harvesting market in the U.S. is estimated at US$72 Million in the year 2020. The country currently accounts for a 30.86% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$34.9 Million in the year 2027 trailing a CAGR of 10.4% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.1% and 7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 6.6% CAGR while Rest of European market (as defined in the study) will reach US$34.9 Million by the year 2027.We bring years of research experience to this 5th edition of our report. The 226-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.
Competitors identified in this market include, among others,
Read the full report: https://www.reportlinker.com/p05798117/?utm_source=PRN
I. INTRODUCTION, METHODOLOGY & REPORT SCOPE I-1
II. EXECUTIVE SUMMARY II-1
1. MARKET OVERVIEW II-1 Cell Harvesting - A Prelude II-1 Impact of Covid-19 and a Looming Global Recession II-1 With Stem Cells Holding Potential to Emerge as Savior for Healthcare System Struggling with COVID-19 Crisis, Demand for Cell Harvesting to Grow II-1 Select Clinical Trials in Progress for MSCs in the Treatment of COVID-19 II-2 Lack of Antiviral Therapy Brings Spotlight on MSCs as Potential Option to Treat Severe Cases of COVID-19 II-3 Stem Cells Garner Significant Attention amid COVID-19 Crisis II-3 Growing R&D Investments & Rising Incidence of Chronic Diseases to Drive the Global Cell Harvesting Market over the Long-term II-3 US Dominates the Global Market, Asia-Pacific to Experience Lucrative Growth Rate II-4 Biopharmaceutical & Biotechnology Firms to Remain Key End-User II-4 Remarkable Progress in Stem Cell Research Unleashes Unlimited Avenues for Regenerative Medicine and Drug Development II-4 Drug Development II-5 Therapeutic Potential II-5
2. FOCUS ON SELECT PLAYERS II-6 Recent Market Activity II-7 Innovations and Advancements II-7
3. MARKET TRENDS & DRIVERS II-8 Development of Regenerative Medicine Accelerates Demand for Cell Harvesting II-8 The Use of Mesenchymal Stem Cells in Regenerative Medicine to Drive the Cell Harvesting Market II-8 Rise in Volume of Orthopedic Procedures Boosts Prospects for Stem Cell, Driving the Cell Harvesting II-9 Exhibit 1: Global Orthopedic Surgical Procedure Volume (2010- 2020) (in Million) II-11 Increasing Demand for Stem Cell Based Bone Grafts: Promising Growth Ahead for Cell Harvesting II-11 Spectacular Advances in Stem Cell R&D Open New Horizons for Regenerative Medicine II-12 Exhibit 2: Global Regenerative Medicines Market by Category (2019): Percentage Breakdown for Biomaterials, Stem Cell Therapies and Tissue Engineering II-13 Stem Cell Transplants Drive the Demand for Cell Harvesting II-13 Rise in Number of Hematopoietic Stem Cell Transplantation Procedures Propels Market Expansion II-15 Growing Incidence of Chronic Diseases to Boost the Demand for Cell Harvesting II-16 Exhibit 3: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040 II-17 Exhibit 4: Global Number of New Cancer Cases and Cancer-related Deaths by Cancer Site for 2018 II-18 Exhibit 5: Number of New Cancer Cases and Deaths (in Million) by Region for 2018 II-19 Exhibit 6: Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others II-19 Exhibit 7: Rising Diabetes Prevalence Presents Opportunity for Cell Harvesting: Number of Adults (20-79) with Diabetes (in Millions) by Region for 2017 and 2045 II-20 Ageing Demographics to Drive Demand for Stem Cell Banking II-20 Global Aging Population Statistics - Opportunity Indicators II-21 Exhibit 8: Expanding Elderly Population Worldwide: Breakdown of Number of People Aged 65+ Years in Million by Geographic Region for the Years 2019 and 2030 II-21 Exhibit 9: Life Expectancy for Select Countries in Number of Years: 2019 II-22 High Cell Density as Major Bottleneck Leads to Innovative Cell Harvesting Methods II-22 Advanced Harvesting Systems to Overcome Centrifugation Issues II-23 Sophisticated Filters for Filtration Challenges II-23 Innovations in Closed Systems Boost Efficiency & Productivity of Cell Harvesting II-23 Enhanced Harvesting and Separation of Micro-Carrier Beads II-24
4. GLOBAL MARKET PERSPECTIVE II-25 Table 1: World Current & Future Analysis for Cell Harvesting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-25
Table 2: World Historic Review for Cell Harvesting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 II-26
Table 3: World 15-Year Perspective for Cell Harvesting by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027 II-27
Table 4: World Current & Future Analysis for Manual by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-28
Table 5: World Historic Review for Manual by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 II-29
Table 6: World 15-Year Perspective for Manual by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 II-30
Table 7: World Current & Future Analysis for Automated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-31
Table 8: World Historic Review for Automated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 II-32
Table 9: World 15-Year Perspective for Automated by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 II-33
Table 10: World Current & Future Analysis for Peripheral Blood by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-34
Table 11: World Historic Review for Peripheral Blood by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 II-35
Table 12: World 15-Year Perspective for Peripheral Blood by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 II-36
Table 13: World Current & Future Analysis for Bone Marrow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-37
Table 14: World Historic Review for Bone Marrow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 II-38
Table 15: World 15-Year Perspective for Bone Marrow by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 II-39
Table 16: World Current & Future Analysis for Umbilical Cord by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-40
Table 17: World Historic Review for Umbilical Cord by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 II-41
Table 18: World 15-Year Perspective for Umbilical Cord by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 II-42
Table 19: World Current & Future Analysis for Adipose Tissue by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-43
Table 20: World Historic Review for Adipose Tissue by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 II-44
Table 21: World 15-Year Perspective for Adipose Tissue by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 II-45
Table 22: World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-46
Table 23: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 II-47
Table 24: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 II-48
Table 25: World Current & Future Analysis for Biotech & Biopharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-49
Table 26: World Historic Review for Biotech & Biopharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 II-50
Table 27: World 15-Year Perspective for Biotech & Biopharma Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 II-51
Table 28: World Current & Future Analysis for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-52
Table 29: World Historic Review for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 II-53
Table 30: World 15-Year Perspective for Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 II-54
Table 31: World Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-55
Table 32: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 II-56
Table 33: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 II-57
III. MARKET ANALYSIS III-1
GEOGRAPHIC MARKET ANALYSIS III-1
UNITED STATES III-1 Increasing Research on Stem Cells for Treating COVID-19 to drive the Cell Harvesting Market III-1 Rising Investments in Stem Cell-based Research Favors Cell Harvesting Market III-1 Exhibit 10: Stem Cell Research Funding in the US (in US$ Million) for the Years 2011 through 2017 III-2 A Strong Regenerative Medicine Market Drives Cell Harvesting Demand III-2 Arthritis III-3 Exhibit 11: Percentage of Population Diagnosed with Arthritis by Age Group III-3 Rapidly Ageing Population: A Major Driving Demand for Cell Harvesting Market III-4 Exhibit 12: North American Elderly Population by Age Group (1975-2050) III-4 Increasing Incidence of Chronic Diseases Drives Focus onto Cell Harvesting III-5 Exhibit 13: CVD in the US: Cardiovascular Disease* Prevalence in Adults by Gender & Age Group III-5 Rising Cancer Cases Spur Growth in Cell Harvesting Market III-5 Exhibit 14: Estimated Number of New Cancer Cases and Deaths in the US (2019) III-6 Exhibit 15: Estimated New Cases of Blood Cancers in the US (2020) - Lymphoma, Leukemia, Myeloma III-7 Exhibit 16: Estimated New Cases of Leukemia in the US: 2020 III-7 Market Analytics III-8 Table 34: USA Current & Future Analysis for Cell Harvesting by Type - Manual and Automated - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-8
Table 35: USA Historic Review for Cell Harvesting by Type - Manual and Automated Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-9
Table 36: USA 15-Year Perspective for Cell Harvesting by Type - Percentage Breakdown of Value Sales for Manual and Automated for the Years 2012, 2020 & 2027 III-10
Table 37: USA Current & Future Analysis for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-11
Table 38: USA Historic Review for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-12
Table 39: USA 15-Year Perspective for Cell Harvesting by Application - Percentage Breakdown of Value Sales for Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications for the Years 2012, 2020 & 2027 III-13
Table 40: USA Current & Future Analysis for Cell Harvesting by End-Use - Biotech & Biopharma Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-14
Table 41: USA Historic Review for Cell Harvesting by End-Use - Biotech & Biopharma Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-15
Table 42: USA 15-Year Perspective for Cell Harvesting by End-Use - Percentage Breakdown of Value Sales for Biotech & Biopharma Companies, Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027 III-16
CANADA III-17 Market Overview III-17 Exhibit 17: Number of New Cancer Cases in Canada: 2019 III-17 Market Analytics III-18 Table 43: Canada Current & Future Analysis for Cell Harvesting by Type - Manual and Automated - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-18
Table 44: Canada Historic Review for Cell Harvesting by Type - Manual and Automated Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-19
Table 45: Canada 15-Year Perspective for Cell Harvesting by Type - Percentage Breakdown of Value Sales for Manual and Automated for the Years 2012, 2020 & 2027 III-20
Table 46: Canada Current & Future Analysis for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-21
Table 47: Canada Historic Review for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-22
Table 48: Canada 15-Year Perspective for Cell Harvesting by Application - Percentage Breakdown of Value Sales for Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications for the Years 2012, 2020 & 2027 III-23
Table 49: Canada Current & Future Analysis for Cell Harvesting by End-Use - Biotech & Biopharma Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-24
Table 50: Canada Historic Review for Cell Harvesting by End-Use - Biotech & Biopharma Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-25
Table 51: Canada 15-Year Perspective for Cell Harvesting by End-Use - Percentage Breakdown of Value Sales for Biotech & Biopharma Companies, Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027 III-26
JAPAN III-27 Increasing Demand for Regenerative Medicine in Geriatric Healthcare and Cancer Care to Drive Demand for Cell Harvesting III-27 Exhibit 18: Japanese Population by Age Group (2015 & 2040): Percentage Share Breakdown of Population for 0-14, 15-64 and 65 & Above Age Groups III-27 Exhibit 19: Cancer Related Incidence and Deaths by Site in Japan: 2018 III-28 Market Analytics III-29 Table 52: Japan Current & Future Analysis for Cell Harvesting by Type - Manual and Automated - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-29
Table 53: Japan Historic Review for Cell Harvesting by Type - Manual and Automated Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-30
Table 54: Japan 15-Year Perspective for Cell Harvesting by Type - Percentage Breakdown of Value Sales for Manual and Automated for the Years 2012, 2020 & 2027 III-31
Table 55: Japan Current & Future Analysis for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-32
Table 56: Japan Historic Review for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-33
Table 57: Japan 15-Year Perspective for Cell Harvesting by Application - Percentage Breakdown of Value Sales for Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications for the Years 2012, 2020 & 2027 III-34
Table 58: Japan Current & Future Analysis for Cell Harvesting by End-Use - Biotech & Biopharma Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-35
Table 59: Japan Historic Review for Cell Harvesting by End-Use - Biotech & Biopharma Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-36
Table 60: Japan 15-Year Perspective for Cell Harvesting by End-Use - Percentage Breakdown of Value Sales for Biotech & Biopharma Companies, Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027 III-37
CHINA III-38 Rising Incidence of Cancer Drives Cell Harvesting Market III-38 Exhibit 20: Number of New Cancer Cases Diagnosed (in Thousands) in China: 2018 III-38 Market Analytics III-39 Table 61: China Current & Future Analysis for Cell Harvesting by Type - Manual and Automated - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-39
Table 62: China Historic Review for Cell Harvesting by Type - Manual and Automated Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-40
Table 63: China 15-Year Perspective for Cell Harvesting by Type - Percentage Breakdown of Value Sales for Manual and Automated for the Years 2012, 2020 & 2027 III-41
Table 64: China Current & Future Analysis for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-42
Table 65: China Historic Review for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-43
Table 66: China 15-Year Perspective for Cell Harvesting by Application - Percentage Breakdown of Value Sales for Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications for the Years 2012, 2020 & 2027 III-44
Table 67: China Current & Future Analysis for Cell Harvesting by End-Use - Biotech & Biopharma Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-45
Table 68: China Historic Review for Cell Harvesting by End-Use - Biotech & Biopharma Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-46
Table 69: China 15-Year Perspective for Cell Harvesting by End-Use - Percentage Breakdown of Value Sales for Biotech & Biopharma Companies, Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027 III-47
EUROPE III-48 Cancer in Europe: Key Statistics III-48 Exhibit 21: Cancer Incidence in Europe: Number of New Cancer Cases (in Thousands) by Site for 2018 III-48 Ageing Population to Drive Demand for Cell Harvesting Market III-49 Exhibit 22: European Population by Age Group (2016, 2030 & 2050): Percentage Share Breakdown by Age Group for 0-14, 15- 64, and 65 & Above III-49 Market Analytics III-50 Table 70: Europe Current & Future Analysis for Cell Harvesting by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 III-50
Table 71: Europe Historic Review for Cell Harvesting by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-51
Table 72: Europe 15-Year Perspective for Cell Harvesting by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027 III-52
Table 73: Europe Current & Future Analysis for Cell Harvesting by Type - Manual and Automated - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-53
Table 74: Europe Historic Review for Cell Harvesting by Type - Manual and Automated Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-54
Table 75: Europe 15-Year Perspective for Cell Harvesting by Type - Percentage Breakdown of Value Sales for Manual and Automated for the Years 2012, 2020 & 2027 III-55
Table 76: Europe Current & Future Analysis for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-56
Table 77: Europe Historic Review for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-57
Table 78: Europe 15-Year Perspective for Cell Harvesting by Application - Percentage Breakdown of Value Sales for Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications for the Years 2012, 2020 & 2027 III-58
Table 79: Europe Current & Future Analysis for Cell Harvesting by End-Use - Biotech & Biopharma Companies, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-59
Table 80: Europe Historic Review for Cell Harvesting by End-Use - Biotech & Biopharma Companies, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-60
Table 81: Europe 15-Year Perspective for Cell Harvesting by End-Use - Percentage Breakdown of Value Sales for Biotech & Biopharma Companies, Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027 III-61
FRANCE III-62 Table 82: France Current & Future Analysis for Cell Harvesting by Type - Manual and Automated - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-62
Table 83: France Historic Review for Cell Harvesting by Type - Manual and Automated Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-63
Table 84: France 15-Year Perspective for Cell Harvesting by Type - Percentage Breakdown of Value Sales for Manual and Automated for the Years 2012, 2020 & 2027 III-64
Table 85: France Current & Future Analysis for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-65
Table 86: France Historic Review for Cell Harvesting by Application - Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 III-66
Table 87: France 15-Year Perspective for Cell Harvesting by Application - Percentage Breakdown of Value Sales for Peripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissue and Other Applications for the Years 2012, 2020 & 2027 III-67
Link:
Global Cell Harvesting Market to Reach US$381,4 Million by the Year 2027 - PRNewswire
- 001 Stem cells for a Webby! [Last Updated On: April 28th, 2010] [Originally Added On: April 28th, 2010]
- 002 Stem cells for a Webby! [Last Updated On: April 28th, 2010] [Originally Added On: April 28th, 2010]
- 003 Latest Cell Therapy Approval by FDA. Dendreon's Provenge. [Last Updated On: April 30th, 2010] [Originally Added On: April 30th, 2010]
- 004 Latest Cell Therapy Approval by FDA. Dendreon's Provenge. [Last Updated On: April 30th, 2010] [Originally Added On: April 30th, 2010]
- 005 Google to Invest in Regenerative Medicine [Last Updated On: May 5th, 2010] [Originally Added On: May 5th, 2010]
- 006 Biotech tax credit appears perfectly designed for cell therapy companies to recoup research dollars spent in 2009-10 [Last Updated On: May 22nd, 2010] [Originally Added On: May 22nd, 2010]
- 007 The changing face of PR and why it matters to regenmed [Last Updated On: June 12th, 2010] [Originally Added On: June 12th, 2010]
- 008 The changing face of PR and why it matters to regenmed [Last Updated On: June 12th, 2010] [Originally Added On: June 12th, 2010]
- 009 Stem Cell Therapy: Age of Human Cell Engineering is Born [Last Updated On: June 25th, 2010] [Originally Added On: June 25th, 2010]
- 010 Using Stem Cells Scientists Grow a Rat Lung, Humans are Next [Last Updated On: June 29th, 2010] [Originally Added On: June 29th, 2010]
- 011 FDA files injunction again Regenerative Sciences citing Regenexx violates regulations [Last Updated On: August 12th, 2010] [Originally Added On: August 12th, 2010]
- 012 FDA files injunction again Regenerative Sciences citing Regenexx violates regulations [Last Updated On: August 12th, 2010] [Originally Added On: August 12th, 2010]
- 013 Careers in cell therapy & regenerative medicine [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 014 Careers in cell therapy & regenerative medicine [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 015 The LinkedIn Cell Therapy Industry Group - 1,000 members strong [Last Updated On: January 18th, 2011] [Originally Added On: January 18th, 2011]
- 016 Cell Therapies: Commercializing a New Class of Biopharmaceuticals [Last Updated On: February 7th, 2011] [Originally Added On: February 7th, 2011]
- 017 The LinkedIn Cell Therapy Industry Group - 1,000 members strong [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 018 Cell Therapies: Commercializing a New Class of Biopharmaceuticals [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 019 In vivo cell trafficking just took a leap forward [Last Updated On: July 3rd, 2011] [Originally Added On: July 3rd, 2011]
- 020 In vivo cell trafficking just took a leap forward [Last Updated On: July 3rd, 2011] [Originally Added On: July 3rd, 2011]
- 021 Cell Therapy's Got Talent Technology Showcase - A Call for Cell Therapy Manufacturing Technology Presentations [Last Updated On: July 10th, 2011] [Originally Added On: July 10th, 2011]
- 022 Cell Therapy's Got Talent Technology Showcase - A Call for Cell Therapy Manufacturing Technology Presentations [Last Updated On: July 10th, 2011] [Originally Added On: July 10th, 2011]
- 023 Clinical trial costs [Last Updated On: July 31st, 2011] [Originally Added On: July 31st, 2011]
- 024 Clinical trial costs [Last Updated On: July 31st, 2011] [Originally Added On: July 31st, 2011]
- 025 Good Data? $100. Good Product Development? $100. Good Commercialization Strategy? Priceless. [Last Updated On: August 14th, 2011] [Originally Added On: August 14th, 2011]
- 026 Good Data? $100. Good Product Development? $100. Good Commercialization Strategy? Priceless. [Last Updated On: August 14th, 2011] [Originally Added On: August 14th, 2011]
- 027 Potential far-reaching implications of the ongoing fight over point-of-care autologous cell therapy [Last Updated On: September 18th, 2011] [Originally Added On: September 18th, 2011]
- 028 Commercial-stage Cell Therapy Companies and Products [Last Updated On: September 18th, 2011] [Originally Added On: September 18th, 2011]
- 029 Potential far-reaching implications of the ongoing fight over point-of-care autologous cell therapy [Last Updated On: September 18th, 2011] [Originally Added On: September 18th, 2011]
- 030 Commercial-stage Cell Therapy Companies and Products [Last Updated On: September 18th, 2011] [Originally Added On: September 18th, 2011]
- 031 Cell Therapy & Regenerative Medicine Domains Available [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- 032 Cell Therapy & Regenerative Medicine Domains Available [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- 033 Dr Farshchian: Regenerative Medicine shows Potentials - Video [Last Updated On: October 14th, 2011] [Originally Added On: October 14th, 2011]
- 034 Mayo Clinic Regenerative Medicine Consult Service - Video [Last Updated On: October 16th, 2011] [Originally Added On: October 16th, 2011]
- 035 Regenerative Medicine and Applications of Stem Cell Research - Video [Last Updated On: October 18th, 2011] [Originally Added On: October 18th, 2011]
- 036 The Future of Stem Cells and Regenerative Medicine - Video [Last Updated On: October 18th, 2011] [Originally Added On: October 18th, 2011]
- 037 "You and Your Health" TV Show - Orthopedic Regenerative Medicine - Video [Last Updated On: October 18th, 2011] [Originally Added On: October 18th, 2011]
- 038 Closing Remarks, Screening Stem Cells 2009: From Reprogramming to Regenerative Medicine - Video [Last Updated On: October 18th, 2011] [Originally Added On: October 18th, 2011]
- 039 Hearing Loss Research: CBR Exclusive! Stem Cells Explored as Cure for Hearing Loss - Video [Last Updated On: October 19th, 2011] [Originally Added On: October 19th, 2011]
- 040 An amazing story of stem cells, regenerative medicine and healing power: - Video [Last Updated On: October 19th, 2011] [Originally Added On: October 19th, 2011]
- 041 What is Regenerative Medicine? | Los Angeles | Hollywood | Beverly Hills - Video [Last Updated On: October 19th, 2011] [Originally Added On: October 19th, 2011]
- 042 A New Era in Regenerative Medicine - Video [Last Updated On: October 20th, 2011] [Originally Added On: October 20th, 2011]
- 043 McEwen Centre for Regenerative Medicine - Video [Last Updated On: October 20th, 2011] [Originally Added On: October 20th, 2011]
- 044 Retroviruses, Reproduction, and Regenerative Medicine: The Influence of Federal Funding - Video [Last Updated On: October 21st, 2011] [Originally Added On: October 21st, 2011]
- 045 You and Your Heath TV Show - Orthopedic Regenerative Medicine Part 1 - Video [Last Updated On: October 21st, 2011] [Originally Added On: October 21st, 2011]
- 046 TEDxPhoenix - Jane Maienschein - Stem Cells, Regenerative Medicine and Us - Video [Last Updated On: October 21st, 2011] [Originally Added On: October 21st, 2011]
- 047 Regenerative Medicine: Pathways to Cure - Version 2.0 - Video [Last Updated On: October 21st, 2011] [Originally Added On: October 21st, 2011]
- 048 Opening Remarks, Screening Stem Cells 2009: From Reprogramming to Regenerative Medicine - Video [Last Updated On: October 23rd, 2011] [Originally Added On: October 23rd, 2011]
- 049 Commercializing Cell-based Regenerative Medicines [Last Updated On: November 13th, 2011] [Originally Added On: November 13th, 2011]
- 050 Commercializing Cell-based Regenerative Medicines [Last Updated On: November 13th, 2011] [Originally Added On: November 13th, 2011]
- 051 Coast To Coast AM - 15.11.2011 - 4/4 - Regenerative Medicine/Dulce Base - Video [Last Updated On: November 17th, 2011] [Originally Added On: November 17th, 2011]
- 052 Coast To Coast AM - 15.11.2011 - 1/4 - Regenerative Medicine/Dulce Base - Video [Last Updated On: November 17th, 2011] [Originally Added On: November 17th, 2011]
- 053 Stem Cell Based Therapies for Blindness: David Hinton - CIRM Science Writer's Seminar - Video [Last Updated On: November 18th, 2011] [Originally Added On: November 18th, 2011]
- 054 Dr. Craig Saunders Discusses Stem Cells and Regenerative Medicine at the Evolution of Fat Workshop - Video [Last Updated On: November 24th, 2011] [Originally Added On: November 24th, 2011]
- 055 Coast To Coast AM: Regenerative Medicine / Dulce Base 11-15-2011 Download Link - Video [Last Updated On: November 24th, 2011] [Originally Added On: November 24th, 2011]
- 056 Sabrina Cohen Foundation Thanks Stem Cell Researchers [Last Updated On: November 27th, 2011] [Originally Added On: November 27th, 2011]
- 057 Sabrina Cohen Foundation Thanks Stem Cell Researchers [Last Updated On: November 27th, 2011] [Originally Added On: November 27th, 2011]
- 058 StemCellTV Talks to Elona Baum of the California Institute of Regenerative Medicine - Video [Last Updated On: December 9th, 2011] [Originally Added On: December 9th, 2011]
- 059 StemCellTV Talks to Michael Werner of Alliance for Regenerative Medicine at Meeting on the Mesa - Video [Last Updated On: December 10th, 2011] [Originally Added On: December 10th, 2011]
- 060 StemCellTV Talks to Morrie Ruffin of Alliance for Regenerative Medicine at Meeting on the Mesa - Video [Last Updated On: December 10th, 2011] [Originally Added On: December 10th, 2011]
- 061 Active phase III or II/III cell therapy trials [Last Updated On: December 11th, 2011] [Originally Added On: December 11th, 2011]
- 062 Active phase III or II/III cell therapy trials [Last Updated On: December 11th, 2011] [Originally Added On: December 11th, 2011]
- 063 2011 Summit: Harnessing Regenerative Medicine for US Service-members, Major General James K. Gilman - Video [Last Updated On: December 17th, 2011] [Originally Added On: December 17th, 2011]
- 064 Recently approved cell therapy products [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- 065 Inactive and recently failed or terminated phase III or II/III cell therapy trials [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- 066 Recently approved cell therapy products [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- 067 Inactive and recently failed or terminated phase III or II/III cell therapy trials [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- 068 Coast To Coast AM: 15.11.2011 - Regenerative Medicine/ Dulce Base - Video [Last Updated On: December 22nd, 2011] [Originally Added On: December 22nd, 2011]
- 069 Stem Cell Clinical Trial for Heart Failure: Eduardo Marban - CIRM Spotlight on Disease - Video [Last Updated On: December 23rd, 2011] [Originally Added On: December 23rd, 2011]
- 070 2011 EMA Committee for Advanced Therapies (CAT) classification record. What can be learned? [Last Updated On: January 1st, 2012] [Originally Added On: January 1st, 2012]
- 071 2011 EMA Committee for Advanced Therapies (CAT) classification record. What can be learned? [Last Updated On: January 1st, 2012] [Originally Added On: January 1st, 2012]
- 072 Regenerative medicine company encouraged by heart failure trial [Last Updated On: January 28th, 2012] [Originally Added On: January 28th, 2012]
- 073 IndiaMART Leaders of Tomorrow AWards 2011 - Regenerative Medical Services Pvt Ltd - Video [Last Updated On: February 8th, 2012] [Originally Added On: February 8th, 2012]
- 074 American CryoStem Joins Alliance for Regenerative Medicine [Last Updated On: February 13th, 2012] [Originally Added On: February 13th, 2012]
- 075 ACT Announces Third Patient with Stargardt’s Disease Treated in U.S. Clinical Trial with RPE Cells Derived from ... [Last Updated On: February 14th, 2012] [Originally Added On: February 14th, 2012]
- 076 Biomask: Improving Facial Burn Treatment for Soldiers in the Field [Last Updated On: February 17th, 2012] [Originally Added On: February 17th, 2012]
- 077 Cytomedix to Showcase Aldagen's Promising Autologous Cell Therapy Technology at Two Regenerative Medicine Meetings [Last Updated On: February 17th, 2012] [Originally Added On: February 17th, 2012]
- 078 Histogenics to Present at 7th Annual New York Stem Cell Summit [Last Updated On: February 17th, 2012] [Originally Added On: February 17th, 2012]
- 079 BioTime CEO Michael D. West to Present at New York Stem Cell Summit [Last Updated On: February 18th, 2012] [Originally Added On: February 18th, 2012]
- 080 Makucell(TM) Announces Key Scientific Presentations and Launch of a Large, Multicenter Use Study of Asymmtate(TM) [Last Updated On: February 22nd, 2012] [Originally Added On: February 22nd, 2012]